Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

Syndax Pharmaceuticals,Inc.
Posted on: 05 Mar 18
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

PR Newswire

WALTHAM, Mass., March 5, 2018

WALTHAM, Mass., March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in two upcoming investor conferences. The details for the two conferences are:

  • The Cowen 38th Annual Health Care Conference at the Boston Marriott Copley Place on Monday, March 12, 2018. Corporate presentation at 4:10 pm ET. 
     
  • Oppenheimer's 28th Annual Healthcare Conference at the Westin New York Grand Central on Wednesday, March 21, 2018. Corporate presentation at 2:45 pm ET. 

A live webcast of these presentations can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLLr. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902

SNDX-G

View original content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences-300607698.html

SOURCE Syndax Pharmaceuticals, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 05/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.